于2025年7月30日，郑北质押735万股股份。2025年7月31日，郑北解除质押761万股股份。 康龙化成（300759）(03759)公布，公司近日接到公司实际控制人之一郑北女士的函告，获悉郑北女士 将其所持有的公司部分股份进行了质押和解除质押。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年8月1日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 证券代码：300759 证券简称：康龙化成 公告编号：2025-039 康龙化成（北京）新药技术股份有限公司 关于 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-039 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 占其 | 占公 | 情况 | | 情况 | | | | 持股数量 | 持股 | 和解质押 | 和解质押 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | 股东名称 | | 比例 | 前质押股 | 后质押股 | 股份 | 股本 | 份限售和 | 质押 | | 质押 | | | （股） | | | | | | | | 份限售和 | | | | | (%) | 份数量 | 份数量 | 比例 | 比例 | 冻结、标 | 股份 | 冻结数量 | 股份 | | | | | （股） | （股） | (%) | (%) | 记数量 | 比例 | （股） | 比例 | | | | | | | | | （股） | (%) | | (%) | | 楼小强 | 60,540,050 | 3 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies have seen the largest increases and decreases in shareholding percentages. Group 1: Increased Holdings - Changfei Optical Fiber Cable (06869) saw the largest increase in holdings, up by 3.06% to a total holding of 41.69% [1][2] - Kanglong Chemical (03759) increased by 2.36%, reaching a holding of 54.24% [1][2] - Yisou Technology (02550) rose by 1.80%, with a current holding of 58.01% [1][2] - Other notable increases include China Zhongjin (01880) with a 0.78% increase to 41.73% and Shanghai Electric (02727) with a 0.76% increase to 43.36% [2] Group 2: Decreased Holdings - Shandong Xinhua Pharmaceutical (00719) experienced the largest decrease, down by 1.74% to a holding of 46.02% [1][3] - Southern Hengsheng Technology (03033) decreased by 0.95%, now holding 61.82% [1][3] - Jihong Co., Ltd. (02603) saw a reduction of 0.91%, with a current holding of 37.85% [1][3] - Other significant decreases include Junshi Biosciences (01877) down by 0.76% to 50.62% and New China Life Insurance (01336) down by 0.71% to 53.23% [3][4] Group 3: Five-Day Changes - Over the last five trading days, Yisou Technology (02550) had the highest increase of 13.77%, reaching 58.01% [5] - Changfei Optical Fiber Cable (06869) increased by 9.53% to 41.69% [5] - The Hang Seng China Enterprises Index (02828) rose by 5.73%, now at 7.19% [5] - Other notable increases include China Energy Construction (03996) up by 5.39% to 21.41% [5] Group 4: Twenty-Day Changes - In the last twenty days, Haotian International Construction (01341) saw the largest increase of 33.88%, reaching 59.80% [8] - Jihong Co., Ltd. (02603) increased by 26.53% to 37.85% [8] - Yisou Technology (02550) rose by 19.75% to 58.01% [8] - Other significant increases include Oriental Electric (01072) up by 15.27% to 43.05% [8] Group 5: Summary of Trends - The data indicates a trend of increasing foreign investment in certain technology and pharmaceutical companies, while traditional sectors like pharmaceuticals and steel are experiencing reductions in foreign holdings [1][5][8]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has strengthened, with companies such as Kanglong Chemical (03759.HK) and WuXi AppTec (02359.HK) rising over 3% [1] - Other companies like Zhaoyan New Drug (06127.HK) and Tiger Med (03347.HK) also experienced gains [1]

Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.68% to 25,562.13 points, while the Tech Index fell by 0.24% to 5,664.02 points, and the National Enterprises Index increased by 0.29% to 9,177.15 points [2][3]. Hang Seng Index Movement - The Hang Seng Index reached a high of 25,660.54 points in the morning but maintained a volatile pattern before closing slightly higher [4]. Sector Performance - Insurance, pharmaceuticals, and brokerage stocks saw collective strength, while coal, shipping, and photovoltaic stocks experienced adjustments [5]. Insurance Sector Strength - Major insurance stocks like AIA Group (up 4.96%), China Pacific Insurance (up 3.91%), and Ping An Insurance (up 3.49%) saw significant gains due to a favorable assessment of life insurance reserve interest rates, which are expected to lower the new business liability costs for insurers [6][7]. Pharmaceutical Sector Boost - Pharmaceutical stocks surged, with companies like Fonda Holdings (up 10.39%), Zhaoyan New Drug (up 6.76%), and Via Biotechnology (up 5.45%) benefiting from overseas licensing deals, including a notable $12.5 billion collaboration between Hengrui Medicine and GlaxoSmithKline [8][9]. Brokerage Sector Gains - Brokerage stocks such as Guotai Junan International (up 9.45%), Shenwan Hongyuan Hong Kong (up 7.32%), and Xingzheng International (up 5.08%) experienced strong performance, likely influenced by the upcoming implementation of the Stablecoin Regulation in Hong Kong [11][13]. Weakness in Cyclical Stocks - Coal, shipping, and photovoltaic stocks faced declines, with companies like Feishang Non-Ferrous Coal (down 15.28%) and COSCO Shipping Ports (down 10.99%) leading the downturn due to falling commodity prices in the futures market [14][18]. Individual Stock Movements - Xuanwu Cloud saw a significant increase of 28% following a strategic partnership with LG Uplus, while Zhejiang United Investment surged by 116.67% on expectations of turning a profit by April 2025 [23][24].

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index dropping over 1%, ending a five-day winning streak, closing at 25,388.35 points, down 1.09% or 278.83 points, with a total turnover of 281.77 billion HKD [1] - Despite the decline, the Hang Seng Index saw a weekly increase of 2.27%, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index rose by 1.83% and 2.51% respectively [1] Blue Chip Performance - WuXi Biologics (02269) led the blue-chip stocks, rising 5.53% to 31.5 HKD, contributing 9.65 points to the Hang Seng Index, following a profit warning indicating a projected 16% revenue growth in the first half of 2025 [2] - Other notable blue-chip performances included SMIC (00981) up 4.98%, Nongfu Spring (09633) up 3.56%, while New Oriental (09901) and Shenzhou International (02313) saw declines of 3.36% and 2.94% respectively [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down nearly 2% and Tencent over 1% [3] - Semiconductor stocks saw a rally, with Hua Hong Semiconductor rising 9% and SMIC up nearly 5% [3] - The pharmaceutical sector experienced gains, driven by a shift towards value assessment in drug procurement, with notable increases in stocks like Kanglong Chemical (03759) up 7.71% and Zhaoyan New Drug (06127) up 7.02% [4] - Airline stocks were active, with China Eastern Airlines (00670) up 3.69% and Air China (00753) up 3.68%, supported by strong summer travel demand [6][7] Regulatory Developments - The National Healthcare Security Administration announced changes to the 11th batch of centralized procurement, moving away from a simple lowest price reference, which is expected to curb vicious price competition and promote a shift towards value-based competition in the pharmaceutical industry [5] - The introduction of new policies aimed at supporting innovative drugs and medical devices was discussed in a recent meeting, indicating a focus on enhancing the clinical application of high-level technological innovations [5] Notable Stock Movements - Valiant Biopharma (09887) saw a significant increase of 91.71% on its debut, closing at 67.1 HKD, following a successful IPO [9] - Jihong Holdings (02603) rose 15.31% after announcing a projected net profit increase of 97.25% to 108.21% for the first half of 2025 [10] - COSCO Shipping Ports (01199) reached a new high, up 9.31%, amid reports of potential acquisitions of port assets [11] - Kintor Pharmaceutical (00148) announced a profit warning, leading to an 8.29% increase in stock price, with expected profits rising over 70% [12] - Lingbao Gold (03330) also saw gains, up 5.89%, with projected revenue growth of 75% to 85% for the first half of 2025 [13]

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen significant inflows and performance, indicating strong investor interest in the innovative drug sector [1][2][5]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) rose nearly 2% today, with a trading volume exceeding 1.3 billion CNY [1]. - As of July 24, the ETF's latest scale surpassed 10.2 billion CNY, leading its peers in the same category [1]. - The ETF's underlying index has shown a 62.78% increase in the first half of 2025, outperforming other medical indices [5][6]. Group 2: Market Dynamics - The ETF has experienced a net inflow of over 230 million CNY in the past four days, reflecting strong market interest [1]. - The financing net purchase amount for the ETF reached 6.2352 million CNY, with the latest financing balance at 206 million CNY [2]. Group 3: Sector Developments - The National Healthcare Security Administration (NHSA) has announced changes to the selection process for medical insurance, moving away from solely considering the lowest bid [3]. - The NHSA's new guidelines are expected to enhance the confidence of companies in R&D investments, particularly in innovative drugs [4]. - The collaboration between dynamic adjustments to the medical insurance catalog and procurement policies is anticipated to shorten the commercialization cycle for innovative drugs [5].

Group 1 - US stock indices showed mixed performance, with the Chinese concept index down by 1.54%. Hong Kong's three major indices opened lower, with the Hang Seng Index down 0.53% and the Hang Seng Tech Index down 0.51% [1] - CXO concept stocks in Hong Kong saw initial gains, with Kanglong Chemical rising over 10%, and other companies like WuXi Biologics and Tigermed also experiencing significant increases [1] - The Hang Seng Medical ETF (513060) opened high and saw a nearly 2% increase, with active trading and a turnover of nearly 800 million yuan, indicating strong investor interest [1] Group 2 - CXO industry leaders are showing signs of stabilization, with expectations for marginal improvements in the second half of the year due to steady growth in R&D investments from the top 30 global pharmaceutical companies [2] - The GLP-1 peptide and small molecule weight loss drug sectors are experiencing high demand, with ample customer orders, while the international situation is expected to stabilize following recent trade negotiations [2] - The anticipated interest rate cuts by the Federal Reserve by 2025 are expected to improve liquidity and revive the global innovative drug industry [2] Group 3 - Focus on the equipment sector's resilience and new technology directions such as AI in healthcare and brain-computer interfaces, as the medical industry faces fewer compliance impacts [3] - The Hang Seng Medical ETF (513060) is highlighted for its efficient layout and strong representation of the medical device, pharmaceutical, and biotechnology sectors, with a low tracking error and high liquidity [3]